ERG oncoprotein expression in prostate cancer: Clonal progression of ERG-positive tumor cells and potential for ERG-based stratification

Prostate Cancer and Prostatic Diseases

Volumn 13, Issue 3, 2010, Pages 228-237

  Furusato, B ^a,b   Tan, S H ^b   Young, D ^a   Dobi, A ^b   Sun, C ^b   Mohamed, A A ^b   Thangapazham, R ^b   Chen, Y ^b   McMaster, G ^c   Sreenath, T ^b   Petrovics, G ^b   McLeod, D G ^b,d   Srivastava, S ^b,e   Sesterhenn, I A ^a  

^a ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^b Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^c Thermo Fisher Scientific   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

^e Center for Prostate Disease Research   (United States)

Author keywords

Clonal selection; ERG; Oncoprotein; Patient stratification; Prostatic intraepithelial neoplasia

Indexed keywords

MONOCLONAL ANTIBODY; ONCOPROTEIN; PROTEIN TMPRSS2; TRANSCRIPTION FACTOR ERG; UNCLASSIFIED DRUG;

ARTICLE; CLONAL VARIATION; CONTROLLED STUDY; CYTOPLASM; GENE FUSION; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; TUMOR CELL; TUMOR DIFFERENTIATION;

ADENOCARCINOMA, MUCINOUS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; ONCOGENE PROTEINS, FUSION; PROGNOSIS; PROSTATIC HYPERPLASIA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED;

EID: 77955716677     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2010.23     Document Type: Article

References (27)

1. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008; 8: 497-511.
2. Petrovics G, Liu A, Shaheduzzaman S, Furusato B, Sun C, Chen Y et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 2005; 24: 3847-3852.
3. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-648.
4. Gopalan A, Leversha MA, Satagopan JM, Zhou Q, Al-Ahmadie HA, Fine SW et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 2009; 69: 1400-1406.
5. Hu Y, Dobi A, Sreenath T, Cook C, Tadase AY, Ravindranath L et al. Delineation of TMPRSS2-ERG splice variants in prostate cancer. Clin Cancer Res 2008; 14: 4719-4725.
6. Klezovitch O, Risk M, Coleman I, Lucas JM, Null M, True LD et al. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci USA 2008; 105: 2105-2110.
7. Sun C, Dobi A, Mohamed A, Li H, Thangapazham RL, Furusato B et al. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 2008; 27: 5348-5353.
8. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008; 10: 177-188.
9. Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 2009; 41: 619-624.
10. King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 2009; 41: 524-526.
11. Zong Y, Xin L, Goldstein AS, Lawson DA, Teitell MA, Witte ON. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc Natl Acad Sci USA 2009; 106: 12465-12470.
12. Clark J, Merson S, Jhavar S, Flohr P, Edwards S, Foster CS et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene 2007; 26: 2667-2673.
13. Barry M, Perner S, Demichelis F, Rubin MA. TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. Urology 2007; 70: 630-633.
14. Mehra R, Han B, Tomlins SA, Wang L, Menon A, Wasco MJ et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res 2007; 67: 7991-7995.
15. Furusato B, Gao CL, Ravindranath L, Chen Y, Cullen J, McLeod DG et al. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod Pathol 2008; 21: 67-75.
16. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H et al. Clustal W and Clustal X version 2.0. Bioinformatics 2007; 23: 2947-2948.
17. Knudsen BS, Allen AN, McLerran DF, Vessella RL, Karademos J, Davies JE et al. Evaluation of the branched-chain DNA assay for measurement of RNA in formalin-fixed tissues. J Mol Diagn 2008; 10: 169-176.
18. Baltzinger M, Mager-Heckel AM, Remy P. Xl erg: expression pattern and overexpression during development plead for a role in endothelial cell differentiation. Dev Dyn 1999; 216: 420-433.
19. Birdsey GM, Dryden NH, Amsellem V, Gebhardt F, Sahnan K, Haskard DO et al. Transcription factor Erg regulates angiogenesis and endothelial apoptosis through VE-cadherin. Blood 2008; 111: 3498-3506.
20. Ellett F, Kile BT, Lieschke GJ. The role of the ETS factor erg in zebrafish vasculogenesis. Mech Dev 2009; 126: 220-229.
21. Clark JP, Cooper CS. ETS gene fusions in prostate cancer. Nat Rev Urol 2009; 6: 429-439.
22. Bonaccorsi L, Nesi G, Nuti F, Paglierani M, Krausz C, Masieri L et al. Persistence of expression of the TMPRSS2: ERG fusion gene after pre-surgery androgen ablation may be associated with early prostate specific antigen relapse of prostate cancer: preliminary results. J Endocrinol Invest 2009; 32: 590-596.
23. Cerveira N, Ribeiro FR, Peixoto A, Costa V, Henrique R, Jeronimo C et al. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 2006; 8: 826-832.
24. Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 2007; 31: 882-888.
25. Han B, Mehra R, Dhanasekaran SM, Yu J, Menon A, Lonigro RJ et al. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5- ETV4 fusion protein in prostate cancer. Cancer Res 2008; 68: 7629-7637.
26. Pflueger D, Rickman DS, Sboner A, Perner S, LaFargue CJ, Svensson MA et al. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia 2009; 11: 804-811.
27. Hameed O, Sublett J, Humphrey PA. Immunohistochemical stains for p63 and alpha-methylacyl-CoA racemase, versus a cocktail comprising both, in the diagnosis of prostatic carcinoma: a comparison of the immunohistochemical staining of 430 foci in radical prostatectomy and needle biopsy tissues. Am J Surg Pathol 2005; 29: 579-587.